 |
 |
Ken--You might be referring to a once-a-day transdermal patch that has just completed Phase IIb clinical trials. It is an agonist which showed "significant efficacy and reduced adverse events in the treatment of patients with mild to severe Parkinson's using this novel transdermal patch." Ron Reiner posted this very interesting press release to the list on February 12th. If you would like the full posting, please let me know. Ann Gibbons